Payment overview · 2025
General Payments
$1,718.46
38 reported records · 13 companies
Healthcare provider profile · identity verified
Sergio Martinez
Allopathic & Osteopathic Physicians|Internal Medicine|Pulmonary Disease · JACKSON HEIGHTS, NY · NPI 1336171040
Verified facts
What the public records show
CMS Open Payments records show Sergio Martinez received $1,718.46 in general payments during 2025 across 38 reported records.
AstraZeneca Pharmaceuticals LP accounted for 37.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Kerendia, Linzess, Ozempic, Rexulti, Rybelsus, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 145 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 139 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 197 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 151 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OFEV as an associated drug or biological on 14236 records involving 6873 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Ofev by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Synjardy by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $637.13 | 37.1% | 13 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $268.70 | 15.6% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $168.41 | 9.8% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $125.00 | 7.3% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $123.73 | 7.2% | 4 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $112.34 | 6.5% | 1 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $82.30 | 4.8% | 4 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $71.92 | 4.2% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $57.65 | 3.4% | 2 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $19.93 | 1.2% | 1 | 2025 |
| Electromed, Inc. | Unresolved — no canonical attribution shown | $19.31 | 1.1% | 2 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $18.58 | 1.1% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $13.46 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,718.46 | 38 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $482.65 | 8 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $168.41 | 3 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $123.88 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $123.73 | 4 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $119.55 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $112.34 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $90.32 | 2 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $82.30 | 4 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $71.92 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $71.11 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $46.57 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $25.27 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $19.93 | 1 | 2025 |
Source payment records
|
|||||
| SMARTVEST Normalized: smartvest |
Device | Electromed, Inc. | $19.31 | 2 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $18.58 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Kerendia kerendia |
2025 | Kerendia | 2024 | 197 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 145 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 105 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 30 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
145 | 44 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
85 | 38 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
139 | 50 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
197 | 46 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
151 | 41 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | OFEV open payments reported associated product |
CMS Open Payments — General Payments 14236 supporting records · 6873 recipient NPIs · example record 1221811762 |
Ofev · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
80 | 27 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
30 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
105 | 35 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
30 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Albuterol Sulfate Hfa | Albuterol Sulfate | 2124 | 607 |
| Montelukast Sodium | Montelukast Sodium | 1463 | 438 |
| Breo Ellipta | Fluticasone/Vilanterol | 693 | 180 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 693 | 155 |
| Atorvastatin Calcium | Atorvastatin Calcium | 640 | 263 |
| Prednisone | Prednisone | 449 | 266 |
| Amlodipine Besylate | Amlodipine Besylate | 442 | 182 |
| Omeprazole | Omeprazole | 426 | 159 |
| Metformin Hcl | Metformin Hcl | 370 | 135 |
| Losartan Potassium | Losartan Potassium | 327 | 113 |
| Alendronate Sodium | Alendronate Sodium | 282 | 78 |
| Levothyroxine Sodium | Levothyroxine Sodium | 276 | 93 |
| Fluticasone Propionate | Fluticasone Propionate | 264 | 120 |
| Tacrolimus | Tacrolimus | 246 | 74 |
| Famotidine | Famotidine | 243 | 91 |
| Vascepa | Icosapent Ethyl | 231 | 64 |
| Simvastatin | Simvastatin | 225 | 69 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 209 | 87 |
| Lisinopril | Lisinopril | 205 | 79 |
| Kerendia | Finerenone | 197 | 46 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 196 | 52 |
| Diclofenac Sodium | Diclofenac Sodium | 188 | 96 |
| Incruse Ellipta | Umeclidinium Bromide | 185 | 39 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 183 | 58 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 180 | 57 |
| Pantoprazole Sodium | Pantoprazole Sodium | 175 | 57 |
| Tamsulosin Hcl | Tamsulosin Hcl | 173 | 62 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 172 | 80 |
| Gabapentin | Gabapentin | 161 | 59 |
| Isoniazid | Isoniazid | 156 | 31 |
| Jardiance | Empagliflozin | 151 | 41 |
| Hydrochlorothiazide | Hydrochlorothiazide | 150 | 54 |
| Azithromycin | Azithromycin | 148 | 123 |
| Linzess | Linaclotide | 145 | 44 |
| Symbicort | Budesonide/Formoterol Fumarate | 139 | 50 |
| Eliquis | Apixaban | 130 | 44 |
| Metoprolol Succinate | Metoprolol Succinate | 121 | 55 |
| Trintellix | Vortioxetine Hydrobromide | 120 | 16 |
| Meclizine Hcl | Meclizine Hcl | 119 | 45 |
| Santyl | Collagenase Clostridium Hist. | 117 | 24 |
| Carvedilol | Carvedilol | 111 | 26 |
| Glipizide Er | Glipizide | 107 | 45 |
| Xiidra | Lifitegrast | 107 | 25 |
| Januvia | Sitagliptin Phosphate | 105 | 25 |
| Ozempic | Semaglutide | 105 | 35 |
| Furosemide | Furosemide | 101 | 35 |
| Naproxen | Naproxen | 101 | 59 |
| Entresto | Sacubitril/Valsartan | 92 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 87 | 28 |
| Glipizide | Glipizide | 86 | 19 |
| Farxiga | Dapagliflozin Propanediol | 85 | 38 |
| Ibuprofen | Ibuprofen | 82 | 40 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 80 | 29 |
| Synjardy | Empagliflozin/Metformin Hcl | 80 | 27 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 79 | 34 |
| Roflumilast | Roflumilast | 77 | 17 |
| Tobradex | Tobramycin/Dexamethasone | 77 | 17 |
| Restasis | Cyclosporine | 76 | 27 |
| Meloxicam | Meloxicam | 73 | 25 |
| Halobetasol Propionate | Halobetasol Propionate | 72 | 33 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 70 | 41 |
| Myrbetriq | Mirabegron | 68 | 15 |
| Nifedipine Er | Nifedipine | 63 | 18 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 61 | 26 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 61 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 59 | 23 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 56 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 56 | 29 |
| Valsartan | Valsartan | 56 | 25 |
| Hydrocortisone | Hydrocortisone | 55 | 21 |
| Ventolin Hfa | Albuterol Sulfate | 55 | 24 |
| Spiriva Respimat | Tiotropium Bromide | 54 | 11 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 53 | 28 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 53 | 17 |
| Pioglitazone Hcl | Pioglitazone Hcl | 51 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 48 | 20 |
| Budesonide Er | Budesonide | 47 | suppressed |
| Lidocaine | Lidocaine | 47 | 28 |
| Atenolol | Atenolol | 46 | 17 |
| Emtricitabine-Tenofovir Disop | Emtricitabine/Tenofovir (Tdf) | 44 | suppressed |
| Epinephrine | Epinephrine | 42 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 42 | 18 |
| Trulicity | Dulaglutide | 41 | 12 |
| Ammonium Lactate | Ammonium Lactate | 40 | 21 |
| Lokelma | Sodium Zirconium Cyclosilicate | 40 | suppressed |
| Ofev | Nintedanib Esylate | 38 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 37 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 37 | 18 |
| Ketoconazole | Ketoconazole | 37 | 22 |
| Metformin Hcl Er | Metformin Hcl | 37 | 21 |
| Mirtazapine | Mirtazapine | 37 | 14 |
| Glimepiride | Glimepiride | 36 | 13 |
| Azelastine Hcl | Azelastine Hcl | 35 | 20 |
| Dicyclomine Hcl | Dicyclomine Hcl | 34 | 13 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 34 | 11 |
| Sertraline Hcl | Sertraline Hcl | 34 | 11 |
| Solifenacin Succinate | Solifenacin Succinate | 34 | suppressed |
| Tradjenta | Linagliptin | 34 | suppressed |
| Ezetimibe | Ezetimibe | 33 | 18 |
| Novolog Flexpen | Insulin Aspart | 33 | 15 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 32 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 32 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 32 | suppressed |
| Estradiol | Estradiol | 31 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 31 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 31 | 20 |
| Single Use Swab | Alcohol Antiseptic Pads | 31 | 22 |
| Telmisartan | Telmisartan | 31 | 16 |
| Icosapent Ethyl | Icosapent Ethyl | 30 | 26 |
| Rexulti | Brexpiprazole | 30 | 11 |
| Ciclopirox | Ciclopirox Olamine | 29 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 29 | 29 |
| Clemastine Fumarate | Clemastine Fumarate | 29 | suppressed |
| Levofloxacin | Levofloxacin | 29 | 26 |
| Procto-Med Hc | Hydrocortisone | 28 | 11 |
| Rybelsus | Semaglutide | 28 | suppressed |
| Xarelto | Rivaroxaban | 28 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 28 | 11 |
| Donepezil Hcl | Donepezil Hcl | 27 | 11 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 26 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 26 | suppressed |
| Memantine Hcl | Memantine Hcl | 26 | suppressed |
| Ursodiol | Ursodiol | 26 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 26 | 15 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 25 | 11 |
| Descovy | Emtricitabine/Tenofov Alafenam | 25 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 25 | suppressed |
| Vraylar | Cariprazine Hcl | 25 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 24 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 24 | 12 |
| Irbesartan | Irbesartan | 24 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 23 | suppressed |
| Chlorthalidone | Chlorthalidone | 22 | 12 |
| Combigan | Brimonidine Tartrate/Timolol | 22 | suppressed |
| Metronidazole | Metronidazole | 22 | suppressed |
| Mounjaro | Tirzepatide | 22 | 12 |
| Synthroid | Levothyroxine Sodium | 22 | suppressed |
| Celecoxib | Celecoxib | 21 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 21 | 12 |
| Auvelity | Dextromethorphan Hbr/Bupropion | 20 | suppressed |
| Latanoprost | Latanoprost | 20 | suppressed |
| Finasteride | Finasteride | 19 | 12 |
| Labetalol Hcl | Labetalol Hcl | 19 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 19 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 19 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 19 | 14 |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 18 | suppressed |
| Fluocinonide | Fluocinonide | 18 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 18 | 17 |
| Mometasone Furoate | Mometasone Furoate | 18 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 18 | 17 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 17 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 17 | suppressed |
| Isentress | Raltegravir Potassium | 17 | suppressed |
| Lumigan | Bimatoprost | 17 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 17 | suppressed |
| Allopurinol | Allopurinol | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Mesalamine | Mesalamine | 16 | suppressed |
| Multaq | Dronedarone Hcl | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 15 | suppressed |
| Clotrimazole | Clotrimazole | 15 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 15 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | suppressed |
| Caplyta | Lumateperone Tosylate | 14 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 13 | suppressed |
| Tivicay | Dolutegravir Sodium | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Rivastigmine | Rivastigmine | 12 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 11 | suppressed |
| Diflorasone Diacetate | Diflorasone Diacetate | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
| Spironolactone | Spironolactone | 11 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 11 | suppressed |
| Zileuton Er | Zileuton | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,718.46 · 38 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, APTIMA, Arikayce, BREZTRI, CREON, INGREZZA, INSPIRE, Kerendia, LINZESS, Ozempic, REXULTI, Rybelsus, SMARTVEST, VRAYLAR, YUPELRI | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Kerendia play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error